Vasoactive Intestinal Peptide as an Intervention: 13 Clinical Trials, Page 1 of 2

1 2

Hide Studies Not Open or Pending


Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

Condition(s):Acute Respiratory Distress Syndrome; Coronavirus; Hypoxic Respiratory Failure; Hypoxemic Respiratory Failure; Respiratory Complication; Respiratory Insufficiency; Cardiac Dysfunction; Pneumonia; Pulmonary Edema; Pulmonary Inflammation; Respiratory Failure; Cytokine Storm; COVID 19; SARS-CoV-2; Cardiac Event; Cardiac Complication; Cardiac Failure; Cardiac InfarctLast Updated:October 6, 2020Recruiting

1 2

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.